Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.
Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.03. The firm had revenue of $0.38 million for the quarter, compared to analysts’ expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 107.48% and a negative net margin of 4,539.55%. On average, analysts expect Syndax Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Syndax Pharmaceuticals stock traded up $0.19 on Tuesday, reaching $8.98. 4,922 shares of the company were exchanged, compared to its average volume of 110,553. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.24 and a current ratio of 6.24. The stock has a 50-day moving average price of $9.02. The stock has a market capitalization of $239.02 million, a price-to-earnings ratio of -3.08 and a beta of 2.41. Syndax Pharmaceuticals has a 1-year low of $3.39 and a 1-year high of $10.17.
In other Syndax Pharmaceuticals news, CEO Briggs Morrison bought 20,400 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average cost of $7.46 per share, for a total transaction of $152,184.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 8.30% of the stock is owned by company insiders.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.
Read More: How dollar cost averaging works
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.